Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from QHSLab ( (USAQ) ) is now available.
On April 21, 2026, QHSLab reported unaudited first-quarter 2026 Integrated Service Program revenue of about $370,000, up from $163,000 a year earlier, marking 127% year-over-year growth driven by expanding provider adoption of its recurring digital care model. Management said the ISP platform helps practices deliver structured, reimbursable care with less workflow burden, reinforcing the company’s positioning as a digital health partner for primary care and specialty providers.
The company also launched its Q-Connect GLP-1 Support Assessment and Personalized Health Journeys Program, designed to support patients on anti-obesity medications, including GLP-1 therapies, and those targeting broader cardiometabolic and lifestyle improvements. By integrating into existing clinical workflows and extending into metabolic and behavioral health, the new offering aims to deepen patient engagement, broaden recurring care opportunities for partner practices and strengthen QHSLab’s footprint in the fast-growing obesity and cardiometabolic care market.
Spark’s Take on USAQ Stock
According to Spark, TipRanks’ AI Analyst, USAQ is a Neutral.
The score is driven primarily by the strong 2025 financial turnaround and balance-sheet deleveraging, reinforced by positive corporate actions to simplify the capital structure. This is tempered by weak technical momentum (bearish RSI/MACD and price below key moving averages) and some sustainability questions due to historically volatile results and weaker cash conversion versus reported earnings.
To see Spark’s full report on USAQ stock, click here.
More about QHSLab
QHSLab, Inc. is a digital health infrastructure company that supports independent primary care and specialty practices with workflow-integrated digital screening, clinical decision support and care management services. The company focuses on scalable, reimbursable care pathways for underdiagnosed behavioral health and chronic conditions and also operates an allergy diagnostics and treatment line under the AllergiEnd brand.
QHSLab generates revenue primarily through recurring service fees from participating medical practices that use its Integrated Service Program platform. Its tools help physicians identify, monitor and manage patients across multiple conditions inside and outside traditional office visits, aiming to enhance clinical outcomes while aligning with existing reimbursement models.
Average Trading Volume: 5,505
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.02M
Learn more about USAQ stock on TipRanks’ Stock Analysis page.